DDX3 regulates DNA damage-induced apoptosis and p53 stabilization.

[1]  L. Attardi,et al.  Deconstructing p53 transcriptional networks in tumor suppression. , 2012, Trends in cell biology.

[2]  R. Jope,et al.  The role of DDX3 in regulating Snail. , 2011, Biochimica et biophysica acta.

[3]  Ya‐Wen Cheng,et al.  Reduced p21WAF1/CIP1 via Alteration of p53-DDX3 Pathway Is Associated with Poor Relapse-Free Survival in Early-Stage Human Papillomavirus–Associated Lung Cancer , 2011, Clinical Cancer Research.

[4]  S. Shieh,et al.  DDX3 Regulates Cell Growth through Translational Control of Cyclin E1 , 2010, Molecular and Cellular Biology.

[5]  Min-Jung Kim,et al.  Activation of p38 Mitogen-Activated Protein Kinase Is Required for Death Receptor–Independent Caspase-8 Activation and Cell Death in Response to Sphingosine , 2009, Molecular Cancer Research.

[6]  Tien-Hsien Chang,et al.  The current understanding of Ded1p/DDX3 homologs from yeast to human , 2009, RNA biology.

[7]  R. Jope,et al.  Identification of an antiapoptotic protein complex at death receptors , 2008, Cell Death and Differentiation.

[8]  Mark P. Jedrychowski,et al.  Human DDX3 functions in translation and interacts with the translation initiation factor eIF3 , 2008, Nucleic acids research.

[9]  F. Vesuna,et al.  Oncogenic role of DDX3 in breast cancer biogenesis , 2008, Oncogene.

[10]  B. Rinkevich,et al.  The DDX3 subfamily of the DEAD box helicases: divergent roles as unveiled by studying different organisms and in vitro assays. , 2007, Current medicinal chemistry.

[11]  N. Kato,et al.  DDX3 DEAD-Box RNA Helicase Is Required for Hepatitis C Virus RNA Replication , 2007, Journal of Virology.

[12]  L. Yang,et al.  A double tyrosine phosphorylation of P68 RNA helicase confers resistance to TRAIL-induced apoptosis , 2007, Oncogene.

[13]  J. Grande,et al.  Involvement of RNA helicases p68 and p72 in colon cancer. , 2007, Cancer research.

[14]  Haizhen Wang,et al.  Phosphorylation of p68 RNA Helicase Plays a Role in Platelet-derived Growth Factor-induced Cell Proliferation by Up-regulating Cyclin D1 and c-Myc Expression* , 2007, Journal of Biological Chemistry.

[15]  Hong Wang,et al.  Inducible resistance of tumor cells to tumor necrosis factor-related apoptosis-inducing ligand receptor 2-mediated apoptosis by generation of a blockade at the death domain function. , 2006, Cancer research.

[16]  F. Fuller-Pace.  DExD/H box RNA helicases: multifunctional proteins with important roles in transcriptional regulation , 2006, Nucleic acids research.

[17]  Yan-Hwa Wu Lee,et al.  DDX3, a DEAD box RNA helicase with tumor growth-suppressive property and transcriptional regulation activity of the p21waf1/cip1 promoter, is a candidate tumor suppressor. , 2006, Cancer research.

[18]  P-C Chang,et al.  DDX3, a DEAD box RNA helicase, is deregulated in hepatitis virus-associated hepatocellular carcinoma and is involved in cell growth control , 2006, Oncogene.

[19]  Brian J. Wilson,et al.  The DEAD box protein p68: a novel transcriptional coactivator of the p53 tumour suppressor , 2005, The EMBO journal.

[20]  C. Ruiz-Ruiz,et al.  GSK-3beta inhibition by lithium confers resistance to chemotherapy-induced apoptosis through the repression of CD95 (Fas/APO-1) expression. , 2004, Experimental cell research.

[21]  K. Jeang,et al.  Requirement of DDX3 DEAD Box RNA Helicase for HIV-1 Rev-RRE Export Function , 2004, Cell.

[22]  J. Pfeilschifter,et al.  p68 DEAD Box RNA Helicase Expression in Keratinocytes , 2004, Journal of Biological Chemistry.

[23]  T. Nishimoto,et al.  Human DDX3Y, the Y-encoded isoform of RNA helicase DDX3, rescues a hamster temperature-sensitive ET24 mutant cell line with a DDX3X mutation. , 2004, Experimental cell research.

[24]  C. Chen,et al.  Diverse cellular transformation capability of overexpressed genes in human hepatocellular carcinoma. , 2004, Biochemical and biophysical research communications.

[25]  L. Maltais,et al.  The human DDX and DHX gene families of putative RNA helicases. , 2003, Genomics.

[26]  M. Oren,et al.  Decision making by p53: life, death and cancer , 2003, Cell Death and Differentiation.

[27]  V. Rotter,et al.  Deconstruction of p53 functions and regulation , 2002, Oncogene.

[28]  Ling Song,et al.  Direct, activating interaction between glycogen synthase kinase-3β and p53 after DNA damage , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[29]  N. Mitsiades,et al.  The role of Fas and FasL as mediators of anticancer chemotherapy. , 2001, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[30]  K. Bhalla,et al.  Antileukemic drugs increase death receptor 5 levels and enhance Apo-2L-induced apoptosis of human acute leukemia cells. , 2000, Blood.

[31]  J. Levine,et al.  Surfing the p53 network , 2000, Nature.

[32]  W. Cavenee,et al.  Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. , 2000, Cancer research.

[33]  A. Owsianka,et al.  Hepatitis C virus core protein interacts with a human DEAD box protein DDX3. , 1999, Virology.

[34]  J. Houghton,et al.  A Fas-dependent component in 5-fluorouracil/leucovorin-induced cytotoxicity in colon carcinoma cells. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[35]  M. Kubbutat,et al.  Regulation of Mdm2-Directed Degradation by the C Terminus of p53 , 1998, Molecular and Cellular Biology.

[36]  D. Green,et al.  DNA damaging agents induce expression of Fas ligand and subsequent apoptosis in T lymphocytes via the activation of NF-kappa B and AP-1. , 1998, Molecular cell.

[37]  J. Houghton,et al.  Thymineless death in colon carcinoma cells is mediated via fas signaling. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[38]  D. Lane,et al.  Regulation of the specific DNA binding function of p53 , 1992, Cell.

[39]  P. Cullen,et al.  Thapsigargin, a tumor promoter, discharges intracellular Ca2+ stores by specific inhibition of the endoplasmic reticulum Ca2(+)-ATPase. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[40]  J. Houghton,et al.  Shared pathways: Death receptors and cytotoxic drugs in cancer therapy , 2009, Pathology Oncology Research.

[41]  P. Linder,et al.  DEAD-box proteins: the driving forces behind RNA metabolism , 2004, Nature Reviews Molecular Cell Biology.

[42]  L. Liu,et al.  DNA topoisomerase poisons as antitumor drugs. , 1989, Annual review of biochemistry.

[43]  U. Rüegg,et al.  Staurosporine, K-252 and UCN-01: potent but nonspecific inhibitors of protein kinases. , 1989, Trends in pharmacological sciences.